Metraipolis › archive › dc_c797ea4fada9

Precision Adjuvant Strategies in Vaccine Development for Substance Use Disorders: Variability and Mechanistic Insights — Europe PMC PMID:41012558

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41012558
DOI
10.3390/pharmaceutics17091223
License (as archived)
solo-consultazione
Archived
2026-11-09T20:28:35.419Z
SHA-256 of the archived text
9f0bf57c5db256b1eeab9cda2d7f9b70108e80f17c79d564f2b9bddfc2d6e9f8
Stable URL of this page
https://metraipolis.com/documento/dc_c797ea4fada9

How to cite

Precision Adjuvant Strategies in Vaccine Development for Substance Use Disorders: Variability and Mechanistic Insights — Europe PMC PMID:41012558 — Europe PMC (en), https://europepmc.org/article/MED/41012558 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c797ea4fada9 (Metraipolis archive dc_c797ea4fada9, sha256 9f0bf57c5db256b1eeab9cda2d7f9b70108e80f17c79d564f2b9bddfc2d6e9f8)
BibTeX
@misc{dcc797ea4fada9,
  title = {Precision Adjuvant Strategies in Vaccine Development for Substance Use Disorders: Variability and Mechanistic Insights — Europe PMC PMID:41012558},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41012558},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c797ea4fada9; sha256 9f0bf57c5db256b1eeab9cda2d7f9b70108e80f17c79d564f2b9bddfc2d6e9f8},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41012558. Agents can read the archived copy with the MCP tool read_document.